iodine i-131 girentuximab

**Iodine I-131 girentuximab** is an investigational CAIX-directed radioimmunotherapy for metastatic clear-cell renal cell carcinoma. It consists of the chimeric IgG1 monoclonal antibody girentuximab, also known as cG250, covalently radiolabeled with iodine-131. The antibody binds carbonic anhydrase IX on clear-cell renal carcinoma cells, concentrating iodine-131 beta radiation at CAIX-positive tumor sites and causing localized radiation-induced DNA damage and tumor-cell death. Phase I and II studies evaluated single and fractionated intravenous administrations in advanced metastatic renal cell carcinoma; hematologic toxicity, particularly thrombocytopenia, was dose-limiting, and the program did not become a marketed therapy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16203819/))

Other names

131I-cG250[131I]cG250I-131-cG250I131-cG250I 131-cG250iodine-131-labeled cG250iodine131-labeled cG250iodine 131-labeled cG250iodine-131-labeled chimeric monoclonal antibody G250iodine131-labeled chimeric monoclonal antibody G250iodine 131-labeled chimeric monoclonal antibody G250iodine-131-labeled girentuximabiodine131-labeled girentuximabiodine 131-labeled girentuximab